## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.8% below STRENGTH zone (3.0-6.0%); PEG 1.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-9.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($13.25)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Securities Fraud Investigation Into Acadia Healthcare Company, Inc. (ACHC) Announced â€“ Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm**
- Source: Business Wire | 20251205T052139 | Neutral | Relevance: 97%
-  Glancy Prongay & Murray LLP has initiated a securities fraud investigation into Acadia Healthcare Company, Inc. (ACHC) after Acadia disclosed an expected increase in patient-related litigation costs, leading to a significant downward revision of its 2025 Adjusted EBITDA guidance. Shareholders who incurred losses are encouraged to contact the firm to learn about potentially recovering their money. The announcement caused Acadia's stock price to drop by 10.9% on December 3, 2025.

**2. Acadia Healthcare Cuts 2025 Outlook After Liability Bomb Went Off**
- Source: Yahoo Finance | 20251204T052139 | Neutral | Relevance: 97%
- Acadia Healthcare (ACHC) has significantly cut its 2025 financial outlook, reducing adjusted EBITDA by $49 million and EPS by 41 cents, due to an unexpected surge in professional and general liability (PLGL) costs. The company now anticipates 2025 PLGL expenses to be $116 million, more than double 2024's $54 million, primarily driven by a 168% spike in claim frequency for the 2025 policy year. This revision places Acadia's adjusted earnings significantly below the Zacks Consensus Estimate and highlights ongoing investor concerns about management discipline and profitability challenges.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 11)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |
| 2025-12-03 | Keybanc | $25 | $30 | -17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |
| 2025-12-03 | Keybanc | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (15.0%, 5.0 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 34.4% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (11 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 15.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.8 |
| Current P/E | 7.4 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_10 deteriorating from 4.5% to -4.8% (-9.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.8pp (needs >3.0% for momentum thesis). Below SMA200 (0.66x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.75% (CS: 8) | Weak |
| RSI_14 | 36.1 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 0.953x | Below |
| vs SMA50 | 0.743x | Below |
| vs SMA200 | 0.656x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $15.47
- **Stop Loss:** $13.25 (14.4% risk)
- **Target:** $17.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 225
- **Position Value:** $3,480.75
- **Portfolio %:** 3.48%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*